Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Top Cited Papers
Open Access
- 13 May 2025
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (13)
Abstract
Metabolic dysfunction–associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver failure. While public health interventions remain essential, therapeutic strategies targeting metabolic dysfunction, inflammation, and fibrosis are urgently needed. This Review focuses on pharmacological treatments in advanced development, including incretin-based therapies (GLP-1, dual, and triple agonists), metabolic modulators (PPAR, FGF21, and THR-β agonists), and novel agents such as fatty acid synthase inhibitors. Current regulatory approval is based on histological end points, with increasing interest in noninvasive biomarkers and personalized treatment approaches. Recent trials with agents such as semaglutide, tirzepatide, survodutide, lanifibranor, pegozafermin, and resmetirom demonstrate substantial promise in resolving MASH and improving fibrosis, but unresolved issues remain regarding treatment duration, response heterogeneity, and long-term adherence. Genetic variants (e.g., PNPLA3 polymorphisms) and emerging molecular biomarkers may enhance stratification, while artificial intelligence is beginning to shape trial design and drug development. As the field moves toward combination therapies and precision medicine, the definition of therapeutic success will likely evolve to reflect both histological improvement and patient-reported outcomes. This Review provides a timely synthesis of the landscape, challenges, and future directions in MASH therapeutics.Keywords
This publication has 52 references indexed in Scilit:
- Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseJAMA, 2024
- A multisociety Delphi consensus statement on new fatty liver disease nomenclatureAnnals of Hepatology, 2023
- Development and Validation of a Score for Fibrotic Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2022
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ ActivityHepatology Communications, 2021
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHHepatology, 2020
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)Diabetologia, 2020
- Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2014
- Detection of vertebral fracturesCurrent Osteoporosis Reports, 2005